Navigation Links
Actavis and Warner Chilcott Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Warner Chilcott
Date:9/27/2013

reflect Actavis' current perspective of existing information as of the date of this release.  It is important to note that Actavis' goals and expectations are not predictions of actual performance. Actual results may differ materially from Actavis' current expectations depending upon a number of factors, risks and uncertainties affecting Actavis' business. These factors include, among others, the inherent uncertainty associated with financial projections; restructuring in connection with, and successful close of, Actavis' acquisition of Warner Chilcott (the "Acquisition"); subsequent integration of the Acquisition and the ability to recognize the anticipated synergies and benefits of the Acquisition; the receipt of required regulatory approvals for the Acquisition (including the approval of antitrust authorities necessary to complete the Acquisition); the difficulty of predicting the timing and outcome of the pending patent litigation concerning certain of the products to be divested pursuant to Actavis' agreement with the U.S. Federal Trade Commission; the anticipated size of the markets and continued demand for Actavis' and Warner Chilcott's products; the impact of competitive products and pricing; access to available financing (including financing for the Acquisition or refinancing of Actavis or Warner Chilcott debt) on a timely basis and on reasonable terms; maintaining a position in the Standard & Poor's 500; the risks of fluctuations in foreign currency exchange rates; the risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insurance on reasonable terms; the difficulty of predicting the timing or outcome of pending or future litigation or government investigations; periodic dependence on a small number of products for a material source of net revenue or income; variabi
'/>"/>
SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Actavis, Inc. to Host Third Quarter 2013 Earnings Conference Call and Webcast
2. Successful Clinical Trials, Recognitions, Enrollment in Studies, Product Launches, and Strategic Announcements - Research Report on Boston Scientific, Gilead, Abbott, Actavis, and Covidien
3. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
4. Actavis Proposed Acquisition of Warner Chilcott Recommended for Approval by Leading Proxy Advisory Firms
5. Actavis Names James DArecca Chief Accounting Officer
6. Actavis Receives Approval from French Competition Authority for Pending Warner Chilcott Acquisition
7. Actavis Announces New Senior Unsecured Term Loan Credit and Guaranty Agreement
8. Actavis and Warner Chilcott Announce Effectiveness of Registration Statement on Form S-4
9. Actavis Announces 42% Increase to $2.01 in Second Quarter 2013 Non-GAAP Earnings Per Share
10. Actavis and Warner Chilcott Receive FTC Second Request Under Hart-Scott-Rodino
11. Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... for the fourth quarter and year ended December 31, ... or less than $0.01 per share, on revenues of ... compares with net income of $195,000, or $0.01 per ... of 2013. The substantial increase in fourth quarter 2014 ...
(Date:3/6/2015)... March 6, 2015  AbbVie (NYSE: ABBV ... Conference on Thursday, March 12, 2015. Richard A. ... in a question and answer session at 8:30 a.m. ... the presentation will be accessible through AbbVie,s Investor Relations ... of the session will be available later that day. ...
(Date:3/6/2015)... de 2015 TeraRecon, ( www.terarecon.com ), ... imagen médica, fortalece su posición dentro del mercado ... Sternberg como director de ventas y de ... Logo - http://photos.prnewswire.com/prnh/20150303/179359LOGO ... las ventas y desarrollo empresarial en Europa, proporcionando ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 2Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 4Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 5TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3
... the Potential Utility of Modigene,s CTP Technology ... ... Va., Sept. 24 Modigene Inc. (OTC,Bulletin Board: MODG) today reported ... journal Endocrinology showing that,erythropoietin (EPO) linked to Modigene,s carboxyl terminal peptide ...
... 24 Iodine has been used as an,antimicrobial ... about molecular,iodine yet many women suffering from Fibrocystic ... may soon yield an effective,nonhormonal treatment. While ... market, all,available hormonal therapies have significant adverse events. ...
Cached Medicine Technology:Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 2Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 3Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 4Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease 2
(Date:3/6/2015)... (PRWEB) March 06, 2015 Los Angeles ... special promotion for Zoom whitening. Zoom is a special type ... professional setting. Unlike other teeth whitening treatments, Zoom does its ... free of stains. For a limited time, Dr. Ghasri is ... from the usual price of $650 and allows patients to ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Dr. Mark Sowell ... Education in Scottsdale, AZ. Offering programs for advanced education in ... over the world. , As a visiting faculty member ... “teach and learn” each time he visits Spear Education to ... Dr. Sowell remarks, “we are training only the top 10% ...
(Date:3/6/2015)... March 06, 2015 Medical Products, Inc., ... an agreement with GE Healthcare to become an authorized ... United States. , MPI has 31 years in distribution ... Healthcare. , With this agreement, MPI will have the ... the healthcare industry. , MPI has always strived ...
(Date:3/6/2015)... March 06, 2015 The Public ... awarded five-year accreditation status to seven more health departments. ... another 1.3 million people can now be assured that ... promote the health of their communities. , Public health ... the health of people and communities. Across the nation, ...
(Date:3/5/2015)... 06, 2015 In 2014, the FDA ... AstraZeneca tops the list scoring 4 drug approvals in ... of all FDA approved drug products, followed by oncology ... as anti-PCSK9, anti-PD1 and CDK inhibitors keep on attracting ... the FDA to treat metastatic melanoma, and at present, ...
Breaking Medicine News(10 mins):Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, is Now Offering a Promotion on Zoom Whitening 2Health News:Plano Dentist Teaches Dentists from Around the Globe at Spear Education 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 3Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3
... visits flood affected states of Tabasco and Chiapas, ... recording artist Clay Aiken today wrapped up the first,leg ... southeast Mexico by,participating in a gift exchange and "sing ... camp erected for flood victims., (Photo: http://www.newscom.com/cgi-bin/prnh/20071225/AQTU002 ...
... Kaiser Permanente is,providing 40 Atlanta-area nonprofit organizations with ... over $1.4 million in grant funds to support,local ... to,$250,000 and focus on increasing access to health ... nursing and pharmacy,scholarships; and other community health programs., ...
... /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ), ... products in the People,s Republic of China, announced ... listing of its common stock on,the NASDAQ Global ... Capital,Market to the NASDAQ Global Market has been ...
... media and PPC ads ... pointed to a landing ... of Key Technology, has hired Denver-based interactive marketing agency,90octane to ... (PPC) advertising will send prospects to a landing,page featuring the ...
... veterans shows that those with injuries to certain parts ... stress disorder (PTSD). The findings, from the National ... Center, suggest that drugs or pacemaker-like devices aimed at ... treatments for PTSD. , PTSD involves the persistent reliving ...
... ... Extension, TUCSON, Ariz., Dec. 21 ImaRx Therapeutics,Inc. ... submitted a lot release,request to the Food and Drug ... urokinase drug product. Urokinase, ImaRx,s first,commercially available FDA-approved product, ...
Cached Medicine News:Health News:Clay Aiken & Family Celebrate Christmas With Survivors of Mexico's Floods 2Health News:Kaiser Permanente Provides $1.4 Million in Holiday Gifts to 40 Metro Atlanta Nonprofits 2Health News:Kaiser Permanente Provides $1.4 Million in Holiday Gifts to 40 Metro Atlanta Nonprofits 3Health News:Chindex International, Inc. Announces Transfer to NASDAQ Global Market 2Health News:Chindex International, Inc. Announces Transfer to NASDAQ Global Market 3Health News:90octane Selected as Interactive Marketing Agency for Symetix Lead Generation Program 2Health News:Study suggests some brain injuries reduce the likelihood of post-traumatic stress disorder 2Health News:Study suggests some brain injuries reduce the likelihood of post-traumatic stress disorder 3Health News:ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating 2Health News:ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating 3
Round serrated handle, polished finish, overall length 130 mm....
... Menicon Super EX is a rigid ... one of its specific characteristics as hard ... correction and show excellent performance against astigmatism. ... material is the combination of fluoromethacrylate, Siloxanylmethacrylate ...
Achievement, available exclusively from Art Optical, is a unique RGP lens design with a patented junctionless back surface and a controlled edge lift....
... Gp is a simultaneous vision ... surface. Through a series of ... the LifeStyle Gp delivers up ... Plus, its multi-aspheric center-distance design ...
Medicine Products: